Nootropics Index - Save on smarter supplements
Nootropics>Synthetic nootropics & research compounds>Metformin
Synthetic nootropics & research compounds

Metformin

Metformin hydrochloride

Metformin is a biguanide medicine supplied as metformin hydrochloride. Evidence for cognition and healthy aging is limited and population-specific; it does not establish better focus or longer life in healthy adults. Compare immediate-release (IR) and extended-release (XR) tablets separately, checking strength, pack count, and every active ingredient in combination products.

Glucose MetabolismIsolated CompoundClinical ResearchLimited Human EvidenceMixed EvidencePopulation Specific EvidenceGi Side Effects
Updated October 2026/7 min read/12 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • Kidney, liver and mitochondrial cautions1The United States label contraindicates use with severe kidney impairment (eGFR below 30 mL/min/1.73 m2) or metabolic acidosis, an abnormal buildup of acid in the blood. Starting metformin is not recommended when eGFR, a measure of kidney filtration, is 30-45. The label also advises avoiding use with liver disease and does not recommend it for mitochondrial diseases such as MELAS or MIDD. Its boxed warning covers potentially fatal lactic acidosis, especially with kidney impairment, low-oxygen illness or other risk factors. These serious cautions concern specific higher-risk groups and remain separate from the healthy-adult base rating.
01

What is it?

What is metformin?

12

Metformin hydrochloride is the salt used in these medicine formulations. IR means immediate release; XR means extended release. The same ingredient name does not make different release systems or combination tablets interchangeable.

What does the cognition evidence show?

3

A 2022 meta-analysis pooling 19 studies found no significant cognitive benefit overall. The studies covered different designs and populations, so the result does not settle every clinical question or support a healthy-adult focus claim.

Why some studies sound more positive

7

A separate 2022 review found a positive cognitive signal in two placebo-controlled studies involving clinical conditions associated with cognitive impairment. That small, selected evidence base explains some optimistic headlines, but it does not establish memory enhancement in healthy users.

Recent human aging research

9

Witham and colleagues (2025) tested metformin for four months in 72 older adults with frailty or prefrailty and probable sarcopenia. It found no improvement in the primary walking-speed outcome and reported more adverse events and hospital admissions in the metformin group. This vulnerable population is not a healthy-adult benchmark.

A preliminary 2026 result

10

A July 2026 preprint in 145 older adults with glucose intolerance reported improvement in a deficit-based frailty index and some biological-age markers over two years, but not a favorable Fried frailty-phenotype result. It was not peer reviewed when checked on October 12, 2026, and did not demonstrate longer lifespan.

02

Names, aliases and forms

Common NameMetformin
Pharmaceutical NameMetformin hydrochloride
Brand NameGlucophage
Cas Number1115-70-4
03

Mechanisms of action

Aging mechanisms are hypotheses

4

Metformin research discusses cellular energy sensing and aging-related pathways. The 2016 aging review is useful mechanistic background; pathway effects and proposed trials are not evidence that a person will live longer.

04

Potential effects and evidence map

Grade C: limited, mixed human evidence for cognitive and aging-related outcomes. Results from selected clinical populations do not establish a healthy-user nootropic or lifespan benefit.

Effect domainMagnitudeGrade
Focus / attention3
UnknownConfidence: Medium

Healthy-adult focus or attention benefits are not established.

Note Cognitive research in clinical populations is indirect for this use.

0/5
E
Memory / learning7
CumulativeConfidence: Medium

Small clinical studies give mixed cognitive findings; healthy-adult memory enhancement remains unproven.

Note A positive two-study clinical pool differs from a broader null synthesis; no general healthy-user conclusion.

1/5
C
Mental energy / wakefulness3
UnknownConfidence: Medium

An acute mental-energy or wakefulness benefit has not been established.

Note An absence of supportive evidence is not proof of no possible effect.

0/5
E
Cellular / long-term brain support10
CumulativeConfidence: Medium

Aging-related human outcomes are mixed and population-specific.

Note Recent clinical trials and preliminary frailty findings do not establish longer life in healthy adults.

1/5
C
05

Typical dosages and timing

Typical
1500-2000 mg/day
Not a recommendation
Lower bound
1500 mg/day
Profile value
Upper bound
2000 mg/day
Profile value
Studied maintenance dose81500-2000 mg/day

This maintenance range comes from a 12-week trial in older adults without chronic disease but with diabetes risk factors, after gradual dose escalation. It is study context, not a validated nootropic dose or a prescription schedule for the reader.

Cited XR label range6500-2000 mg/day

The cited XR label starts at the lower amount once daily and allows increases up to the upper amount. These are formulation-specific prescribing details, not the maximum for every metformin product or instructions for self-directed use.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
Half-life1Acute
6.2 hours
Study window8Cumulative
12 weeks
Plasma timing is not an effect window1

The featured The time for blood levels to fall by half during the final elimination phase.Source is approximately 6.2 hours in plasma under label pharmacokinetic conditions; kidney impairment can prolong it. It does not measure how long a cognitive effect lasts. The study window refers to the exercise trial, not a recommended cycle.

07

Safety, side effects and risk profile

Why the base risk is moderate8
For oral hydrochloride at the featured study doses over weeks, tolerability can be dose-limiting: 8 of 27 metformin participants needed a dose reduction for GI discomfort in the exercise trial. That supports moderate rather than low concern. The participants had diabetes risk factors, so the frequency is not a universal healthy-user estimate; legal status and special-population cautions do not drive this base label.
Legal / regulatory risk1
Confidence: High

In the United States, metformin is a prescription medicine as of October 12, 2026.

Note Jurisdiction-specific access context; it does not determine intrinsic base risk.

2/5
A
Interaction risk6
Confidence: High

Insulin or sulfonylureas increase low-blood-glucose risk; excessive alcohol and some clearance-altering drugs increase other risks.

Note Drug combinations require their own assessment; plain-metformin evidence cannot be transferred wholesale.

3/5
A
GI discomfort8
Confidence: Medium

Gastrointestinal effects can be dose-limiting at studied oral doses.

Note In the 12-week exercise study, GI discomfort prompted dose reduction in 8/27 metformin participants versus 3/26 placebo participants.

3/5
B
Evidence uncertainty3
Confidence: Medium

Cognitive benefits in healthy adults remain unproven.

Note Evidence gaps limit benefit claims; uncertainty alone does not raise the base risk.

1/5
C
Pregnancy / lactation caution1
Confidence: High

Pregnancy and breastfeeding require an indication-specific assessment; this page does not establish nootropic use in either group.

Note These populations are outside the generally healthy nonpregnant adult base case.

2/5
A
Headache / dizziness1
Confidence: High

Headache is listed among common adverse reactions in clinical trials.

Note A tolerability observation, not evidence of improved alertness or productivity.

1/5
A
Vitamin B12 with longer use5

A 4.3-year placebo-controlled trial in adults with type 2 diabetes using insulin found more B12 deficiency with metformin. Its population and dose limit direct extrapolation to healthy users; it supports a longer-term nutrient caution rather than an inevitable side effect for everyone.

B12 monitoring context11

UK MHRA advice identifies higher dose, longer use and existing risk factors as reasons B12 reduction becomes more likely. It advises testing when deficiency is suspected and considering periodic monitoring in at-risk patients.

08

Interactions and cautions

Medication and procedure cautions6

Insulin and sulfonylureas increase hypoglycemia risk. Excessive alcohol, drugs that reduce metformin clearance, and carbonic-anhydrase inhibitors can increase lactic-acidosis risk. Contrast imaging, surgery with restricted intake, dehydration and hypoxic illness require individual prescribing assessment.

09

Legal and regulatory status

United States prescription status1

As of October 12, 2026, the cited United States label classifies metformin as a prescription medicine. Online listings do not establish dispensing or import eligibility. Requirements in other jurisdictions need separate local verification.

10

How it compares

IR and XR: compare like with like6

Match the release type before comparing price. XR changes drug release and has product-specific administration requirements. The cited XR tablets are swallowed whole, so splitting or crushing them is not equivalent to changing a plain tablet serving. Tablet count alone cannot establish equivalent use.

11

Practical buying and quality notes

  • Compare plain metformin separately from products whose ingredient panel lists another active drug. Read each ingredient strength separately: another ingredient's amount is not the metformin amount. Check the complete composition and selected pack before comparing prices.
  • For the same release type and ingredient composition, divide pack price by tablet count, then compare equal tablet strengths. For example, 60 tablets labeled 500 mg each contain 30 g of labeled metformin hydrochloride. This arithmetic describes pack contents, not a dosing recommendation or product ranking.6
  • Some catalog form labels say capsules even when the merchant title says tablets. Combination strengths and older offer data can also need correction. Verify the selected variant, full ingredient list, pack count, current price and stock at the merchant; do not rely on a suspect price-per-milligram field.
  • Compare shipping, currency and dispensing requirements as well as pack price. A listing is a navigation lead, not confirmation that the product is suitable, available for delivery, or lawful to obtain in your location.
12

FAQ

What dose has been studied?

8

The dose section gives an exercise-trial maintenance range and separate XR-label context. Neither establishes a dose for healthy-user cognitive enhancement; study participants, formulation and clinical purpose matter.

How long does metformin last, and should it be cycled?

1

A plasma half-life is a drug-clearance measure, not a cognitive duration. The reviewed studies do not establish a nootropic onset or an evidence-based on/off cycle for healthy adults. Trial duration describes observation time rather than how long a reader should take it.

13

References

  1. DailyMed. Metformin hydrochloride tablets, Quallent Pharmaceuticals. U.S. prescribing information, updated August 12, 2026.
  2. U.S. FDA Drug Safety Communication. FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2016.
  3. The effect of metformin on cognitive function: A systematic review and meta-analysis. J Psychopharmacol. 2022.
  4. Metformin as a Tool to Target Aging. Cell Metab. 2016.
  5. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010.
  6. DailyMed. Metformin hydrochloride extended-release tablets. U.S. prescribing information.
  7. Nibber A et al. Investigating the pro-cognitive and anti-depressant efficacy of metformin: a systematic review and meta-analysis of randomised controlled trials. J Affect Disord. 2022;310:52-59.
  8. Konopka AR et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18:e12880.
  9. Witham MD et al. Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty (MET-PREVENT). Lancet Healthy Longev. 2025;6:100695.
  10. Musi N et al. A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance. medRxiv preprint. July 28, 2026.
  11. UK MHRA. Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk. June 20, 2022.
  12. PubChem. Metformin hydrochloride, CID 14219.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.